Table 6

Allele frequencies in clinically distinct subgroups of the CLL cohort

CLL subgroupAllele frequency
P vs CLLP vs counterpart
No.CG
Sex 
    Female 105 0.82 0.18 .38 .12 
    Male 143 0.77 0.23 .56 .04 
Binet stage 
    A+C 195 0.80 0.20 .43 .03 
    B 49 0.74 0.26 .40 .27 
Affected LN areas 
    2 or less 188 0.81 0.19 .50 <.001 
    More than 2 50 0.66 0.34 .14 .051 
Spleen size 
    Normal 191 0.81 0.19 .29 <.001 
    Enlarged 51 0.72 0.28 .11 .027 
LDH 
    450 IU/L or less 192 0.81 0.19 .01 .003 
    More than 450 IU/L 34 0.65 0.35 .64 <.001 
Lines of therapy 
    Less than 2 170 0.81 0.19 .41 <.001 
    2 or more 67 0.72 0.28 .11 .018 
CLL subgroupAllele frequency
P vs CLLP vs counterpart
No.CG
Sex 
    Female 105 0.82 0.18 .38 .12 
    Male 143 0.77 0.23 .56 .04 
Binet stage 
    A+C 195 0.80 0.20 .43 .03 
    B 49 0.74 0.26 .40 .27 
Affected LN areas 
    2 or less 188 0.81 0.19 .50 <.001 
    More than 2 50 0.66 0.34 .14 .051 
Spleen size 
    Normal 191 0.81 0.19 .29 <.001 
    Enlarged 51 0.72 0.28 .11 .027 
LDH 
    450 IU/L or less 192 0.81 0.19 .01 .003 
    More than 450 IU/L 34 0.65 0.35 .64 <.001 
Lines of therapy 
    Less than 2 170 0.81 0.19 .41 <.001 
    2 or more 67 0.72 0.28 .11 .018 
Close Modal

or Create an Account

Close Modal
Close Modal